Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02790476 · ClinicalTrials.gov registry record · NA
Behavioral Insights to Encourage Judicious Prescribing of Opioids
A NA study, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 851
- Enrollment target
NCT02790476: Completed NA study, sponsored by University of Southern California.
NCT02790476 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 851 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02790476, a NA study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 851 participants
- Enrollment target
Study Summary
In collaboration with the San Diego Medical Examiner's Office and the State of California's controlled Substance Utilization Review and Evaluation System (CURES), the investigators propose to review opioid poisonings over the past 12 months and will send letters to prescribers in California when at least one of the provider's prescription(s) was filled by a patient who died of an opioid poisoning in San Diego County. The letters will be non-judgmental and factual, explaining that a patient of the provider who was being treated with prescription narcotics died of an opioid poisoning. The letter will also encourage judicious prescribing including use of the CURES system before prescribing. The investigators will evaluate physician prescribing practices over 24 months 12 months pre- and 12 months post-letter using data from the CURES database. The investigators' hypothesis is that letters will make the risk of opioids more cognitively available and that physicians will respond by prescribing opioids more carefully. This will result in fewer deaths due to misuse and more frequent use of the CURES system.
Primary Outcome
The hypothesis is that the average change over time in dispensed narcotic represented as monthly morphine milligram equivalent (MME) dose will be larger for prescribers receiving the letter intervention, compared to the average change over time for the control prescribers not receiving the letter intervention.
Interventions
- OTHER Letters
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 851 participants |
| Start Date | 2017-01-27 |
| Est. Completion | 2018-02-27 |
| Phase | NA |
What the finished NCT02790476 record still lists
NCT02790476 is an interventional study that assigns participants to a tested intervention. The registered 851 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 1 intervention - of which Letters is the first listed.
NCT02790476 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02790476 about?
NCT02790476 is a clinical study titled "Behavioral Insights to Encourage Judicious Prescribing of Opioids". In collaboration with the San Diego Medical Examiner's Office and the State of California's controlled Substance Utilization Review and Evaluation System (CURES), the investigators propose to review opioid poisonings over the past 12 months and will send letters to prescribers in California when at ...
What is the current status of trial NCT02790476?
This trial is currently completed. It is a NA study. The enrollment target is 851 participants. The study started on 2017-01-27. Estimated completion is 2018-02-27.
What interventions are being tested in trial NCT02790476?
The interventions under investigation include: Letters (OTHER).
Who is sponsoring clinical trial NCT02790476?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02790476's enrollment target sits among peer trials
851 131st of 2000 higher than 1,870 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06422143 · 851 participants · Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- NCT06237452 · 852 participants · Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI